Screener
Iovance Biotherapeutics, Inc. IOVA Business Segments — Cost Of Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Product revenue, net | $99,313 | $59,952 | $170,743 | $109,276 |
| Total revenue | 99,313 | 59,952 | 170,743 | 109,276 |
| Costs and expenses * | ||||
| Cost of sales ** | $43,595 | $48,881 | $86,093 | $91,595 |
| Research and development ** | 58,851 | 77,928 | 121,338 | 153,895 |
| Selling, general, and administrative ** | 39,272 | 37,567 | 78,221 | 81,366 |
| Depreciation and amortization | 9,500 | 9,350 | 18,039 | 17,415 |
| Total costs and expenses | $151,218 | $173,726 | $303,691 | $344,271 |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s business segments — cost of revenue?
- Iovance Biotherapeutics, Inc. (IOVA) reported business segments — cost of revenue of $43.6M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s business segments — cost of revenue changed year-over-year?
- Iovance Biotherapeutics, Inc.'s business segments — cost of revenue decreased by 10.8% year-over-year, from $48.88M to $43.6M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s business segments — cost of revenue?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s business segments — cost of revenue has grown at a 1194.8% compound annual growth rate (CAGR), from $1.03M to $173.18M.
- What does business segments — cost of revenue mean?
- This encompasses the total direct costs incurred to generate revenue, including manufacturing, royalties, and other direct service expenses. It is the primary metric for assessing the segment's gross profitability and the scalability of the production process.
Ask your AI about Iovance Biotherapeutics, Inc.'s business segments — cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude